PriceTargets.com logo

Vera Therapeutics - VERA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.22
  • Forecasted Upside: 39.02%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 2 Strong Buy Ratings
$42.60 As of 12/20/2024 06:17 PM ET
▲ +0.55 (1.31%)

This chart shows the closing price for VERA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERA

Analyst Price Target is $59.22
▲ +39.02% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $59.22, with a high forecast of $107.00 and a low forecast of $25.00. The average price target represents a 39.02% upside from the last price of $42.60.

This chart shows the closing price for VERA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Vera Therapeutics. This rating has held steady since December 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2024
  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024

Latest Recommendations

  • 2 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2024Wells Fargo & CompanyInitiated CoverageOverweight$70.00
11/8/2024WedbushBoost TargetNeutral ➝ Neutral$30.00 ➝ $38.00
11/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$72.00 ➝ $75.00
10/28/2024GuggenheimBoost TargetBuy ➝ Buy$56.00 ➝ $64.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$60.00
10/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/16/2024Evercore ISIUpgradeStrong-Buy
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/6/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00 ➝ $107.00
9/3/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$62.00 ➝ $72.00
8/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$65.00 ➝ $62.00
5/31/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$60.00 ➝ $65.00
5/10/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$57.00 ➝ $68.00
4/5/2024GuggenheimReiterated RatingBuy ➝ Buy$56.00
3/27/2024GuggenheimBoost TargetBuy ➝ Buy$27.00 ➝ $56.00
3/21/2024WedbushBoost TargetNeutral ➝ Neutral$21.00 ➝ $34.00
1/26/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$29.00 ➝ $37.00
1/26/2024WedbushBoost TargetNeutral ➝ Neutral$16.00 ➝ $21.00
1/25/2024OppenheimerInitiated CoverageOutperform$26.00
1/8/2024Cantor FitzgeraldInitiated CoverageOverweight
12/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00
12/18/2023Raymond JamesInitiated CoverageOutperform$29.00
11/30/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$25.00 ➝ $22.00
11/10/2023Jefferies Financial GroupUpgradeHold ➝ Buy$18.00 ➝ $26.00
9/26/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $25.00
8/15/2023GuggenheimInitiated CoverageBuy$27.00
8/11/2023WedbushBoost TargetNeutral ➝ Neutral$12.00 ➝ $16.00
5/12/2023WedbushBoost Target$6.00 ➝ $9.00
5/12/2023HC WainwrightLower Target$11.00 ➝ $10.00
4/12/2023JPMorgan Chase & Co.Lower TargetOverweight$38.00 ➝ $22.00
3/29/2023HC WainwrightLower TargetBuy$15.00 ➝ $11.00
1/4/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$32.00 ➝ $6.00
1/4/2023WedbushDowngradeOutperform ➝ Neutral$33.00 ➝ $8.00
1/4/2023HC WainwrightLower TargetBuy$36.00 ➝ $15.00
11/18/2022JPMorgan Chase & Co.Boost TargetOverweight$35.00 ➝ $38.00
8/22/2022HC WainwrightBoost TargetBuy$35.00 ➝ $36.00
7/12/2022JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
5/2/2022HC WainwrightInitiated CoverageBuy$35.00
4/18/2022WedbushInitiated CoverageOutperform$32.00
3/28/2022Lifesci CapitalReiterated RatingOutperform
6/8/2021Evercore ISIInitiated CoverageOutperform$24.00
6/8/2021Jefferies Financial GroupInitiated CoverageBuy
6/8/2021CowenInitiated CoverageOutperform
(Data available from 12/23/2019 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 15 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 17 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 15 very positive mentions
  • 30 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vera Therapeutics logo
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $42.60
Low: $40.96
High: $45.06

50 Day Range

MA: $45.27
Low: $39.79
High: $49.75

52 Week Range

Now: $42.60
Low: $14.20
High: $51.61

Volume

2,228,091 shs

Average Volume

876,029 shs

Market Capitalization

$2.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Vera Therapeutics?

The following Wall Street analysts have issued stock ratings on Vera Therapeutics in the last twelve months: Cantor Fitzgerald, Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Raymond James, Scotiabank, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for VERA.

What is the current price target for Vera Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Vera Therapeutics in the last year. Their average twelve-month price target is $59.22, suggesting a possible upside of 39.0%. Cantor Fitzgerald has the highest price target set, predicting VERA will reach $107.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $25.00 for Vera Therapeutics in the next year.
View the latest price targets for VERA.

What is the current consensus analyst rating for Vera Therapeutics?

Vera Therapeutics currently has 1 hold rating, 7 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERA will outperform the market and that investors should add to their positions of Vera Therapeutics.
View the latest ratings for VERA.

What other companies compete with Vera Therapeutics?

Other companies that are similar to Vera Therapeutics include Qiagen, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Revolution Medicines. Learn More about companies similar to Vera Therapeutics.

How do I contact Vera Therapeutics' investor relations team?

The company's listed phone number is 650-770-0077 and its investor relations email address is [email protected]. The official website for Vera Therapeutics is veratx.com. Learn More about contacing Vera Therapeutics investor relations.